Premium
Effect of a mammary‐derived growth inhibitor on the expression of the oncogenes c‐fos, c‐myc and c‐ras
Author(s) -
Lehmann W.,
Strauss M.,
Kießling U.,
Graetz H.,
Koberling A.,
Langen P.
Publication year - 1989
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/0014-5793(89)81189-5
Subject(s) - biology , mammary carcinoma , messenger rna , microbiology and biotechnology , gene expression , cell growth , growth inhibition , cancer research , gene , genetics , carcinoma
A mammary‐derived growth inhibitor (MDGI) inhibits the resumption of growth of stationary Ehrlich ascites carcinoma (EAC) cells in vitro. The present study shows that the resumption of growth is accompanied by a rapid increase of the steady state mRNA level of the proto‐oncogenes c‐fos, c‐myc and c‐ras, which is reduced by MDGI. EAC cells from the exponential growth phase insensitive to MDGI did not show a reduced RNA expression. The effect of MDGI represents a novel activity at the level of gene expression and suggests a link to exist between growth inhibition and the reduction of c‐fos, c‐myc and c‐ras expression.